Recent studies have shown that patients with glioma have higher expression of some immunosuppression related genes, such as LGALS1 and IGFBP2, and blocking the expression of immune-inhibiting related genes can remodel the immunosuppression microenvironment (41, 42). The gene discussed is IGFBP2; the disease is central nervous system cancer.